Published in Antimicrob Agents Chemother on November 01, 1978
Key issues concerning fungistatic versus fungicidal drugs. Eur J Clin Microbiol Infect Dis (1997) 1.04
Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother (1997) 0.94
KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis. Antimicrob Agents Chemother (1998) 0.81
Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection. Antimicrob Agents Chemother (2005) 0.77
Comparative activities of Bay n7133, ICI 153,066, and ketoconazole in murine cryptococcosis. Antimicrob Agents Chemother (1983) 0.76
Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med (1974) 6.75
A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis (1969) 5.58
Activated macrophages in congenitally athymic "nude mice" and in lethally irradiate mice. J Immunol (1975) 3.96
Listeria monocytogenes infection in nude mice. Infect Immun (1975) 2.82
Cell-mediated immunity in Cryptococcosis. Cell Immunol (1974) 2.68
The wide spectrum of cryptococcal infections. Am J Med (1972) 2.42
Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B. Antimicrob Agents Chemother (1975) 2.17
Significance of T cells in resistance to experimental murine coccidioidomycosis. Infect Immun (1977) 2.14
Acute systemic candidiasis in normal and congenitally thymic-deficient (nude) mice. J Reticuloendothel Soc (1976) 2.07
Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol (1975) 1.99
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
Rubidium release: a rapid and sensitive assay for amphotericin B. J Infect Dis (1976) 1.76
Anomalous high native resistance to athymic mice to bacterial pathogens. Infect Immun (1977) 1.75
Tumoricidal responses in vitro of peritoneal macrophages from conventionally housed and germ-free nude mice. Cell Immunol (1976) 1.58
Fungal infection following renal transplantation. Arch Intern Med (1975) 1.48
Effects of stimulation and suppression of cell-mediated immunity on experimental cryptococcosis. Infect Immun (1977) 1.48
Host defense in cryptococcosis. I. An in vivo model for evaluating immune response. Int Arch Allergy Appl Immunol (1978) 1.38
Histoplasma capsulatum infection in nude mice. Infect Immun (1978) 1.31
Nocardia infections in congenitally athymic (nude) mice and in other inbred mouse strains. Infect Immun (1977) 1.26
Experimental mycobacterial infection in congenitally athymic "nude" mice. J Reticuloendothel Soc (1976) 1.21
Enhanced primary resistance to Listeria monocytogenes in T cell-deprived mice. Immunology (1977) 1.17
Pulmonary cryptococcosis: clinical forms and treatment. A Center for Disease Control cooperative mycoses study. Am Rev Respir Dis (1973) 1.16
Macrophage activation in congenitally athymic mice raised under conventional or germ-free conditions. J Reticuloendothel Soc (1977) 1.14
Morphology and time course of experimental listeriosis in nude mice. Infect Immun (1976) 1.11
Host defense against the pneumococcus in T-lymphocyte-deficient, nude mice. Infect Immun (1975) 1.01
Treatment of experimental murine cryptococcosis: a comparison of miconazole and amphotericin B. Antimicrob Agents Chemother (1978) 0.79
Antibody responses in nude mice injected with limiting numbers of congenic thymus cells. Cell Immunol (1977) 0.78
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Pneumonia due to Chlamydia trachomatis in the immunocompromised (nude) mouse. J Infect Dis (1981) 3.19
A cluster of Rhodococcus (Gordona) Bronchialis sternal-wound infections after coronary-artery bypass surgery. N Engl J Med (1991) 2.73
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Cell-mediated immunity in Cryptococcosis. Cell Immunol (1974) 2.68
Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. J Infect Dis (1974) 2.61
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med (1994) 2.60
Factors governing adherence of Candida species to plastic surfaces. Infect Immun (1985) 2.57
Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 2.36
International outbreak of Salmonella Eastbourne infection traced to contaminated chocolate. Lancet (1975) 2.32
Coccidioidomycosis. Part I. Am Rev Respir Dis (1978) 2.25
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy. Am J Med (1968) 2.18
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B. Antimicrob Agents Chemother (1975) 2.17
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli. Antimicrob Agents Chemother (1983) 2.11
Cloning and expression of Legionella pneumophila antigens in Escherichia coli. Infect Immun (1984) 2.03
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis (1984) 2.03
Adherence and penetration of vascular endothelium by Candida yeasts. Infect Immun (1983) 2.02
Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci (1979) 2.02
Coccidioidomycosis: factors affecting the host-parasite interaction. J Infect Dis (1983) 2.02
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med (1996) 1.91
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
Nosocomial pneumonia. A continuing major problem. Am Rev Respir Dis (1973) 1.91
Typhoid fever. An epidemic with remarkably few clinical signs and symptoms. Arch Intern Med (1984) 1.88
Coccidioidomycosis. Part II. Am Rev Respir Dis (1978) 1.83
Excretion pathways of amphotericin B. J Infect Dis (1979) 1.82
Outbreak of central-nervous-system toxoplasmosis in western Europe and North America. Lancet (1983) 1.80
Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis (1982) 1.77
Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother (1981) 1.77
Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). J Med Vet Mycol (1986) 1.69
Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1996) 1.68
Penetration of brain abscess by systemically administered antibiotics. J Neurosurg (1973) 1.68
Disseminated mycobacteriosis due to Mycobacterium abcessus in two recipients of renal homografts. Am Rev Respir Dis (1974) 1.66
Efficacy of SCH39304 in murine cryptococcosis. Antimicrob Agents Chemother (1989) 1.61
Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol (2008) 1.60
Passive immunization in murine cryptococcosis. Sabouraudia (1981) 1.59
Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis (1981) 1.58
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
In vitro antifungal susceptibility testing and measurement of levels of antifungal agents in body fluids. Rev Infect Dis (1987) 1.58
Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol (1990) 1.57
The clinical spectrum of endemic psittacosis. Arch Intern Med (1967) 1.56
Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med (1983) 1.56
Incorporation of tritiated thymidine by leprosy bacilli in cultures of human lepromatous macrophages. J Infect Dis (1972) 1.54
Host defense in cryptococcosis. II. Cryptococcosis in the nude mouse. Cell Immunol (1978) 1.52
Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol (1985) 1.52
High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med (1984) 1.51
The continuous bacteremia of lepromatous leprosy. N Engl J Med (1972) 1.49
Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother (1986) 1.49
Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis (1990) 1.46
Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother (1997) 1.46
Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med (1988) 1.45
Detection of Paracoccidioides brasiliensis in tissue samples by a nested PCR assay. J Clin Microbiol (2000) 1.44
Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1996) 1.41
Variability of sequential studies of lymphocyte blastogenesis in normal adults. Clin Exp Immunol (1976) 1.40
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis (2001) 1.39
Host defense in cryptococcosis. I. An in vivo model for evaluating immune response. Int Arch Allergy Appl Immunol (1978) 1.38
Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother (1992) 1.37
Host defense in cryptococcosis. III. Protection of nude mice by thymus transplantation. J Infect Dis (1979) 1.36
Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs (1983) 1.35
Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother (1985) 1.34
Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother (1987) 1.34
High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Intern Med (1983) 1.33
Double blind fluid therapy evaluation in pediatric cholera. Pediatrics (1969) 1.33
Histoplasma capsulatum infection in nude mice. Infect Immun (1978) 1.31
Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob Agents Chemother (1996) 1.28
Immunologic and clinical improvement of progressive coccidioidomycosis following administration of transfer factor. Cell Immunol (1973) 1.27
Fungal infections in AIDS patients. J Med Vet Mycol (1992) 1.27
Diagnosis and monitoring of murine histoplasmosis by a nested PCR assay. J Clin Microbiol (2001) 1.27
Bacterial interference in the therapy of recurrent staphylococcal infections. Multiple abscesses due to the implantation of the 502A strain of staphylococcus. N Engl J Med (1966) 1.26
Relationship of progesterone- and estradiol-binding proteins in Coccidioides immitis to coccidioidal dissemination in pregnancy. Infect Immun (1983) 1.25
Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am Rev Respir Dis (1986) 1.23
Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother (1997) 1.23
Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. Am J Med (1988) 1.22
Human sex hormones stimulate the growth and maturation of Coccidioides immitis. Infect Immun (1981) 1.21
Immunologic studies of disseminated infection with Aspergillus fumigatus in the nude mouse. J Infect Dis (1981) 1.20
Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother (1998) 1.19
Toxoplasmosis presenting as panhypopituitarism in a patient with the acquired immune deficiency syndrome. Am J Med (1984) 1.19
Itraconazole treatment of murine aspergillosis. Sabouraudia (1985) 1.16
Intracellular and extracellular defenses of human phagocytes against Blastomyces dermatitidis conidia and yeasts. J Lab Clin Med (1985) 1.15